Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.50 +0.65%

+$0.34 today

Market cap
$17.22B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 2.82M

Average 2.55M

EXEL EBITDA Margin

EBITDA as a percentage of revenue.

Exelixis, Inc.NASDAQ: EXEL

EBITDA Margin · Q2 FY2026 · quarter ended Jul 2026

EBITDA Margin widens to 42.9%

EBITDA Margin was 42.9% in Q2 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 43.0%, up 6.3 pp year over year. Over 3 fiscal years it widened by 23.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 53.3% for the fiscal year ending Jan 2027, up from 39.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJul 2026
42.9%-2.1 pp QoQ
Last fiscal yearJan 2026
39.7%+6.6 pp YoY
LTMJul 2026
43.0%+6.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp+1.8 pp+0.8 pp
1 year+6.6 pp+13.5 pp+7.0 pp
3 years+23.9 pp+11.1 pp-12.8 pp
5 years+24.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
39.7%
Year-over-year change
+6.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 EBITDA Margin of 43.0% is the 2nd highest of the 7 companies compared; the peer median is 31.9%.
  • Its year-over-year change of +6.3 pp is the 4th highest of 6, against a peer median of +16.8 pp.
  • Over three fiscal years its change of +23.9 pp compares with a peer median of +16.6 pp.
EXEL Competitors Peer median
EBITDA Margin for EXEL and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
HCMHUTCHMED (China) LimitedLTM Jun 2025-1.2% +16.8 pp+86.5 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-74.8% +669.1 pp—
RVMDRevolution Medicines, Inc.FY2025— ——
Peer median (excluding EXEL) 31.9%+16.8 pp+16.6 pp

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.